Management of Acute Decompensated Heart Failure in Biventricular Cardiomyopathy

Initial Assessment and Monitoring

The European Society of Cardiology recommends immediate ECG and echocardiography in all patients with suspected ADHF to assess cardiac structure and function, particularly in biventricular involvement 1, 3
Measurement of plasma natriuretic peptide levels is recommended upon presentation to help differentiate ADHF from non-cardiac causes of dyspnea, with a strength of evidence based on multiple studies 1
Regular monitoring of symptoms, urine output, renal function, and electrolytes is essential during intravenous diuretic therapy, as recommended by the American Heart Association 1, 2
Patients with cardiogenic shock should be rapidly transferred to a tertiary care center with 24/7 cardiac catheterization capability and ICU/CCU with availability of mechanical circulatory support, according to the European Heart Journal 1

The European Society of Cardiology recommends an initial dose of 20-40 mg IV furosemide for new-onset ADHF or those with chronic decompensated HF not receiving oral diuretics 1
For patients on chronic diuretic therapy, the initial IV dose should be at least equivalent to their oral dose, as stated by the European Heart Journal 1
Diuretics can be administered either as intermittent boluses or continuous infusion, with dose and duration adjusted according to the patient's symptoms and clinical status, based on evidence from the Circulation journal 1, 2
When diuresis is inadequate, intensify the diuretic regimen by increasing doses of intravenous loop diuretics or adding a second diuretic, as recommended by the American College of Cardiology 2, 4

Intravenous nitroglycerin, nitroprusside, or nesiritide may be considered as adjuncts to diuretic therapy for stable patients with ADHF, according to the American Heart Association 2
Inotropic agents are not recommended unless the patient is symptomatically hypotensive or shows signs of hypoperfusion, due to safety concerns, as stated by the European Society of Cardiology 1, 2
Low-dose dopamine infusion may be considered alongside loop diuretic therapy to improve diuresis and better preserve renal function, based on evidence from the Circulation journal 2, 4

For congestion with adequate blood pressure, IV diuretics are the mainstay of therapy, as recommended by the European Journal of Heart Failure 5
For hypertensive ADHF, vasodilators with close monitoring and low-dose diuretic treatment are recommended, according to the European Journal of Heart Failure 5
For cardiogenic shock, fluid challenge if clinically indicated, followed by inotropic therapy if SBP remains <90 mmHg, and consider mechanical circulatory support for potentially reversible causes, as stated by the European Journal of Heart Failure 5, 3

The European Society of Cardiology recommends continuing evidence-based, disease-modifying therapies in patients with worsening of chronic HFrEF, in the absence of hemodynamic instability or contraindications 1, 2
If beta-blocker therapy needs to be temporarily reduced or omitted due to hemodynamic instability, it should be reinitiated before discharge once the patient is stable, as recommended by the European Journal of Heart Failure 5
Initiation of beta-blocker therapy is recommended after optimization of volume status and successful discontinuation of intravenous diuretics, vasodilators, and inotropic agents, based on evidence from the Circulation journal 2, 4

Ultrafiltration may be considered for patients with obvious volume overload or refractory congestion, as recommended by the American College of Cardiology 2, 6
For patients with biventricular failure who cannot be stabilized with medical therapy, mechanical circulatory support systems should be considered, according to the European Journal of Heart Failure 3
For cardiogenic shock, consider intra-aortic balloon pump and evaluation for mechanical circulatory support devices, as stated by the European Journal of Heart Failure 5, 3

Patients are medically fit for discharge when hemodynamically stable, euvolemic, established on evidence-based oral medication, and with stable renal function for at least 24 hours, as recommended by the European Journal of Heart Failure 3
Follow-up with a general practitioner within 1 week of discharge and with the hospital cardiology team within 2 weeks is recommended, according to the European Journal of Heart Failure 3
Enrollment in a multidisciplinary heart failure management program is recommended to reduce the risk of HF hospitalization and mortality, as stated by the European Heart Journal 1, 3

NSAIDs and COX-2 inhibitors should be avoided as they increase the risk of HF worsening and hospitalization, according to the European Heart Journal 1